Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 16/20 | 0.44 |
| ▸ | JAK2 | O60674 | 14/20 | 0.44 |
| ▸ | JAK1 | P23458 | 11/20 | 0.44 |
| ▸ | TYK2 | P29597 | 6/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.38 |
| ▸ | AXL | P30530 | 3/20 | 0.38 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.38 |
| ▸ | MERTK | Q12866 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671731 | 0.90 | BRAF (0.39) | JAK3JAK2JAK1TYK2 | |
| SCHEMBL671917 | 0.88 | JAK3 (0.41) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL12797343 | 0.88 | JAK3 (0.46) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL12797333 | 0.87 | JAK3 (0.44) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL672111 | 0.84 | JAK3 (0.42) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL673367 | 0.83 | JAK3 (0.42) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL12797280 | 0.83 | JAK3 (0.58) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL671487 | 0.82 | JAK3 (0.50) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL10204812 | 0.82 | JAK3 (0.46) | JAK3JAK2JAK1TYK2HDAC6 | |
| SCHEMBL12797328 | 0.80 | JAK3 (0.42) | JAK3JAK2JAK1TYK2AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | claimed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | claimed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-9242987-B2 | Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors | CELLZOME LIMITED (GB) | 2016-01-26 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252779-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS | JAK1, JAK3, JAK2 | JAK3 2/4885JAK2 3/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.